Fulgent Q2 FY26 GAAP net loss widens to $29.5 million; revenue rises to $85.4 million

Reuters2026/07/30 20:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fulgent Genetics posted Q2 2026 revenue of $85.4 million, up 4.38% from a year earlier.
GAAP net loss attributable to shareholders widened to $29.5 million, or $(1.05) per share, from $19 million, or $(0.62) per share.
Adjusted EBITDA loss increased to $17.1 million from $3 million.
Management cited processing delays tied to the final phase of a revenue cycle management and billing system transition as it cut full-year revenue guidance to $330 million-$340 million.
CEO Ming Hsieh highlighted Phase 2 FID-007 data presented at ASCO, ongoing progress for FID-007 and FID-022, and efficiency gains from AI tools.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260730017288) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fulgent Q2 FY26 GAAP net loss widens to $29.5 million; revenue rises to $85.4 million

You may also like

Crypto prices